ATNM - Actinium Pharmaceuticals, Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

150.8M

Cash

84.06M

Avg Qtr Burn

-9.908M

Short % of Float

7.40%

Insider Ownership

2.13%

Institutional Own.

26.92%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Iomab-B (CD45) (apamistamab-I-131) Details Hematopoietic cell transplantation , Acute myeloid leukemia	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Actimab-A + venetoclax Details Relapsed/refractory acute myeloid leukemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iomab-ACT (CAR-T – CD45) Details Lymphoma, Diffuse large B cell lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Actimab-A + CLAG-M Details Relapsed/refractory acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iomab-ACT (CAR-T – CD45) Details Sickle cell disease, Blood disorder	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iomab-ACT (GeneTx – CD45) Details Lymphoma, Acute radiation syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Actimab-A + venetoclax Details Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.